Journal of Biomedical Engineering Research (대한의용생체공학회:의공학회지)

The Korean Society of Medical and Biological Engineering (대한의용생체공학회)
권호 표지
DOI QR코드

DOI QR Code

Development of Evaluation Method for Drug Release Propreties in Drug Eluting Stent

약물방출스텐트의 약물 방출 특성 평가 방법 개발

  • Song, J.M. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) ;
  • Baek, H. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) ;
  • Lee, S.Y. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) ;
  • Jang, D.H. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) ;
  • Seo, M.Y. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) ;
  • Park, G.J. (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute) ;
  • Maeng, Eun-Ho (Medical Device Team, Medical Device Assessment Headquarter, Korea Testing & Research institute)
  • 송정민 (한국화학융합시험연구원 의료기기본부 의료용품팀) ;
  • 백홍 (한국화학융합시험연구원 의료기기본부 의료용품팀) ;
  • 이승영 (한국화학융합시험연구원 의료기기본부 의료용품팀) ;
  • 장동혁 (한국화학융합시험연구원 의료기기본부 의료용품팀) ;
  • 서무엽 (한국화학융합시험연구원 의료기기본부 의료용품팀) ;
  • 박길종 (한국화학융합시험연구원 의료기기본부 의료용품팀) ;
  • 맹은호 (한국화학융합시험연구원 의료기기본부 의료용품팀)
  • Received : 2013.03.12
  • Accepted : 2013.05.29
  • Published : 2013.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The goal of this study is to develop test method for evaluating the drug eluting properties of drug eluting stents (DES). PBS and the detergent solutions, presented by each DES manufacturer, were used for drug release of DES coated with paclitaxel, zotarolimus and everolimus. The drugs which are coating DES were not released by PBS but released by the detergent solutions, finally paclitaxel 83.38%, zotarolimus 103.85% and everolimus 115.78%. It seems that the use of the detergents is necessary in order to release the drugs because those drugs are extremely hydrophobic. In conclusion, using of detergent solutions presented by each manufacturer were suitable for evaluating the drug eluting property of drug eluting stent.

Keywords

References

  1. 한국보건산업진흥원, 스텐트 시장동향, 2005.
  2. P. A. Lemos, P. W. Serruys, R. T. Domburg, F. Saia, C. A. Arampatzis, A. Hoye, M. Degertekin, K. Tanabe, J. Daemen, T. K. K. Liu, E. McFadden, G. Sianos, S. H. Hofma, P. C. Smits, W. J. Giessen and P. J. Feyter, "Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the Real World," Circulation, vol. 109, pp. 190-195, 2004. https://doi.org/10.1161/01.CIR.0000109138.84579.FA
  3. S. J. Park, "Drug-Eluting Stent : Present and Future," J. Korean Med. Assoc. vol. 51, no. 4, pp. 299-305, 2008. https://doi.org/10.5124/jkma.2008.51.4.299
  4. A. Seidlitz, S. Nagel, B. Semmling, K. Sternberg, H. K. Kroemer, W. Weitschies, "In vitro Dissolution Testing of Drug- Eluting Stents," Current Pharmaceutical Biotechnology, vol. 14, pp. 67-75, 2013.
  5. R. S. Schwartz, E. R. Edelman, A. Carter, N. Chronos, C. Regoers, K. A. Robinson, R. Waksman, J. Weinberger, R. L. Wilensky, D. N. Jenson, B. D. Zuckerman, E. Virmani, "Drug-Eluting Stents in Preclinical Studies: Recommendation Evaluation from a Consensus Group," Circulation, vol. 106, pp. 1867-1873, 2002. https://doi.org/10.1161/01.CIR.0000033485.20594.6F
  6. W. Khan, S. Farah, A. Nyska, A. J. Domb, "Carrier Free Rapamycin Loaded Drug Eluting Stent: In Vitro and In vivo Evaluation," J Control Release, vol. 168, no. 1, pp. 70-76, 2013. https://doi.org/10.1016/j.jconrel.2013.02.012
  7. C. P. Naseerali, P. R. Hari, K. Sreenivasan, "The Release Kinetics of Drug Eluting Stents Containing Sirolimus as Coated Drug: Role of Release Media," J Chromatogr B Analyt Biomed Life Sci, vol. 878, pp. 709-712, 2010. https://doi.org/10.1016/j.jchromb.2010.01.023
  8. S. Farah, W. Kahn, A. J. Domb, "Crystalline Coating of Rapamycin onto a Stent: Process Development and Characterization," Int J Pharm, vol. 10, 99.20-28, 2013.
  9. K. Steigerwald, S. Merl, A. Kastrati, A. Wienczorek, M. Vorpahl, R. Mannhold, M. Vogeser, J. Hausleiter, M. Joner, A. Schomig, R. Wessely, "The Pre-clinical Assessment of Rapamycin-Eluting, Durable Polymer-Free Stent Coating Concepts," Biomaterials, pp. 1-6, 2008.
  10. R. S. Schwartz, E. Edelman, R. Virmani, A. Carter, J. F. Granada, G. L. Kaluza, N. A. F. Chronos, K. A. Robinson, R. Waksman, J. Weinberger, G. J. Wilson, R. L. Wilensky, "Drug- Eluting Stents in Preclinical Studies: Updated Concensus Recommendations for Preclinical Evaluation," Circ Cardiovasc Intervent, pp. 141-153, 2008.
  11. M. Merciadez, L. Alquier, R. Mehta, A. Patel, A. Wang, "A Novel Method for the Elution of Sirolimus (Rapamycin) in Drug-Eluting Stents," Dissolution Technolodies, vol. 18, pp. 37-42, 2011. https://doi.org/10.14227/DT180411P37
  12. F. C. Nelson, S. J. Stachel, C. P. Eng, S. N. Seghal, "Manipulation of the C(22)-C(27) Region of Rapamycin: Stability Issues and Biological Implications," Bioorg Med Chem Lett, vol. 9, pp. 295-300, 1999. https://doi.org/10.1016/S0960-894X(98)00735-5